The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 18, 2020
Filed:
Aug. 22, 2018
Applicant:
University of Southern California, Los Angeles, CA (US);
Inventors:
Jean C. Shih, Beverly Hills, CA (US);
Florence M. Hofman, Venice, CA (US);
Thomas C. Chen, La Canada Flintridge, CA (US);
Assignee:
University of Southern California, Los Angeles, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/165 (2006.01); A61K 31/277 (2006.01); A61K 31/404 (2006.01); A61K 31/5375 (2006.01); A61K 31/4188 (2006.01); A61K 31/4045 (2006.01); C07D 209/24 (2006.01); A61K 31/137 (2006.01); A61K 45/06 (2006.01); A61K 31/352 (2006.01); A61K 31/357 (2006.01); A61K 31/381 (2006.01); C12N 15/113 (2010.01); A61K 31/135 (2006.01); A61K 31/138 (2006.01); A61K 31/15 (2006.01); A61K 31/366 (2006.01); A61K 31/405 (2006.01); A61K 31/495 (2006.01); A61K 49/16 (2006.01); C07D 209/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5375 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/138 (2013.01); A61K 31/15 (2013.01); A61K 31/352 (2013.01); A61K 31/357 (2013.01); A61K 31/366 (2013.01); A61K 31/381 (2013.01); A61K 31/405 (2013.01); A61K 31/4045 (2013.01); A61K 31/4188 (2013.01); A61K 31/495 (2013.01); A61K 45/06 (2013.01); A61K 49/16 (2013.01); C07D 209/14 (2013.01); C07D 209/24 (2013.01); C12N 15/1137 (2013.01); C12Y 104/03004 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01);
Abstract
A pharmaceutical composition and method for treating brain cancer are provided. The method includes administering to a patient in need thereof an effective amount of one or more compounds that include moclobemide, clorgyline, clorgyline's Near-infra-red dye Monoamine Oxidase Inhibitor (NMI), and MHI 148-clorgyline, and their salt thereof. The composition and method are particularly effective in reducing the size of glioblastomas that are temozolomide (TMZ) resistant.